Even though Canonsburg, Pa.-based Mylan Pharmaceuticals agreed in October to pay $465 million to settle a U.S. Department of Justice investigation into EpiPen, the company is still working on finalizing the settlement, Fortune reports.
Here’s what you need to know.
1. The U.S. Justice Department and other agencies have not confirmed the settlement.
2. Mylan said it is now in the final stage of closing its settlement.
3. The Justice Department is investing Mylan over its decision to raise the costs of its EpiPen. The EpiPen projects to account for 6 percent of Mylan’s total sales in 2017.
Source: (Becker’s ASC Review)